Free Trial

Bright Minds Biosciences (DRUG) SEC Filings & 10K Form

Bright Minds Biosciences logo
$39.61 -3.34 (-7.78%)
(As of 11/15/2024 ET)

Recent Bright Minds Biosciences SEC Filings

DateFilerForm TypeView
11/06/2024
3:20 PM
Bright Minds Biosciences (Issuer)
Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2024
3:06 PM
Bright Minds Biosciences (Subject)
Cormorant Asset Management, LP (Filed by)
Form SC 13G/A
11/05/2024
2:21 PM
Bright Minds Biosciences (Subject)
McDonald Ian (Filed by)
Form SC 13D/A
11/05/2024
2:25 PM
Bright Minds Biosciences (Subject)
McDonald Ian (Filed by)
Form SC 13D/A
10/23/2024
5:01 PM
Bright Minds Biosciences (Subject)
Point72 Asset Management, L.P. (Filed by)
Form SC 13G
10/23/2024
5:09 PM
Bright Minds Biosciences (Subject)
Logos Global Management LP (Filed by)
Form SC 13G
10/22/2024
3:02 PM
Bright Minds Biosciences (Subject)
PFM Health Sciences, LP (Filed by)
Form SC 13G/A
10/22/2024
3:03 PM
Bright Minds Biosciences (Subject)
Cormorant Asset Management, LP (Filed by)
Form SC 13G
10/21/2024
8:17 PM
Bright Minds Biosciences (Filer)
Form D
Notice of Exempt Offering of Securities 
10/18/2024
3:02 PM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/17/2024
4:07 PM
Bright Minds Biosciences (Issuer)
Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/17/2024
4:11 PM
Bright Minds Biosciences (Issuer)
Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2024
12:14 PM
Bright Minds Biosciences (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13G
10/16/2024
10:38 AM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/16/2024
10:43 AM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/03/2024
10:36 AM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/12/2024
11:58 AM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/14/2024
8:15 PM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/26/2024
7:18 PM
Bright Minds Biosciences (Subject)
McDonald Ian (Filed by)
Form SC 13D/A
02/26/2024
7:10 PM
Bright Minds Biosciences (Subject)
McDonald Ian (Filed by)
Form SC 13D/A
02/12/2024
8:56 PM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/18/2024
11:57 AM
Bright Minds Biosciences (Subject)
McDonald Ian (Filed by)
Form SC 13D
12/29/2023
3:30 PM
Bright Minds Biosciences (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
12/22/2023
5:26 PM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/08/2023
5:00 AM
Bright Minds Biosciences (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:DRUG) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners